scispace - formally typeset
J

Jaime L. Schneider

Researcher at Yeshiva University

Publications -  6
Citations -  5253

Jaime L. Schneider is an academic researcher from Yeshiva University. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 4808 citations.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Daniel J. Klionsky, +2522 more
- 01 Jan 2016 - 
TL;DR: Author(s): Klionsky, DJ; Abdelmohsen, K; Abe, A; Abedin, MJ; Abeliovich, H; A Frozena, AA; Adachi, H, Adeli, K, Adhihetty, PJ; Adler, SG; Agam, G; Agarwal, R; Aghi, MK; Agnello, M; Agostinis, P; Aguilar, PV; Aguirre-Ghis

5th Conference on Advances in Molecular Mechanisms Underlying Neurological Disorders

TL;DR: This dual role as ‘saviour’ and ‘victim’ in the context of neurodegeneration for chaperone-mediated autophagy, a cellular pathway involved in the selective degradation of cytosolic proteins in lysosomes is described.
Journal ArticleDOI

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

TL;DR: In this paper , the authors conducted a phase 2 study to evaluate the intracranial efficacy of lorlatinib in patients with metastatic ROS1-rearranged lung cancer who developed CNS-only progression on crizotinib.